Cardiovascular Toxicities of Ibrutinib: A Pharmacovigilance Study Based on the United States Food and Drug Administration Adverse Event Reporting System Database

Background: Although ibrutinib has been widely used to treat haematological malignancies, many studies have reported associated cardiovascular events. These studies were primarily animal experiments and clinical trials. For more rational clinical drug use, a study based on post-marketing data is nec...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Yi, Guo, Xiaojing, Chen, Chenxin, Chi, Lijie, Guo, Zhijian, Liang, Jizhou, Wei, Lianhui, Chen, Xiao, Ye, Xiaofei, He, Jia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863914/
https://www.ncbi.nlm.nih.gov/pubmed/36678594
http://dx.doi.org/10.3390/ph16010098

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863914/
https://www.ncbi.nlm.nih.gov/pubmed/36678594
http://dx.doi.org/10.3390/ph16010098

Ejemplares similares